Table 2.
Summary of meta-analyses of randomized controlled trials of latanoprost and other PG analogs in patients with glaucoma or ocular hypertension: occurrence of conjunctival hyperemia
| Study | Studies analyzed | Conjunctival hyperemia |
|---|---|---|
| Cucherat et al50 | 21 studies with LAT (BAK-preserved and preservative-free), BIMf (BAK-preserved), TRA (preserved with BAK, polyquaternium-1, or sofZia), or TAF (BAK-preserved) over ≥2 months. | Significantly higher risk with polyquaternium-1 TRA (odds ratio [95% CI]: 0.24 [0.11;0.55]), sofZia TRA (odds ratio [95% CI]: 0.37 [0.16;0.84]), BAK BIM 0.03% (odds ratio [95% CI]: 0.18 [0.10;0.33]), BAK BIM 0.01% (odds ratio [95% CI]: 0.27 [0.13;0.56]), BAK TAF (odds ratio [95% CI]: 0.18 [0.05;0.65]), BAK TRA (odds ratio [95% CI]: 0.25 [0.14;0.46]), and BAK LAT (odds ratio [95% CI]: 0.52 [0.31;0.86]) than with BAK-free LAT. |
| Orme et al42 | 72 studies of 19 different single or combination treatment regimens in 14,849 patients. | LAT monotherapy had a significantly (P<0.05) lower odds of hyperemia-type events than TRA, BIM, TRA plus TIM, and BIM plus TIM. |
| Honrubia et al66 | Meta-analysis specifically designed to assess conjunctival hyperemia. 13 studies in 2,222 patients treated for 2 weeks to 9 months compared LAT versus TRA (5 studies), LAT versus BIM (7 studies), and LAT versus TRA versus BIM (1 study). | Significantly higher risk with TRA than LAT (odds ratio 0.51; P<0.0001; 95% CI 0.39–0.67) and with BIM than LAT (odds ratio 0.32; P<0.0001; 95% CI 0.24–0.42). |
| Eyawo et al41 | Out of 15 studies in 2,755 patients treated for 3–12 months, 6 compared LAT and TRA, 5 compared LAT and BIM, and 1 compared BIM and TRA. | Significantly higher risk with TRA than LAT (relative risk 5.71; P≤0.001; 95% CI 1.81–18.02), with BIM than LAT (relative risk 1.59; P=0.04; 95% CI 1.02–2.48), and with TRA than BIM (relative risk 0.82; P=0.02; 95% CI 0.69–0.97). |
| Aptel et al45 | 8 studies in 1,610 patients treated with LAT, BIM, or TRA for 1–6 months. | Significantly higher incidence with BIM than LAT (relative risk 0.59; P<0.001; 95% CI 0.50–0.69) or TRA (relative risk 0.84; P=0.05; 95% CI 0.70–1.00). |
| Cheng and Wei46 | 13 studies in 1,302 patients treated with LAT or BIM for 1–6 months. | Significantly higher frequency with BIM than LAT (rate difference 20%; 95% CI 15–24). |
| Stewart et al48 | 11 studies in 386 patients treated with LAT, BIM, TRA, or non-PG analogs for 1–2 months. | Significantly higher incidence with TRA (23%; P<0.001) than any other treatment. Incidence 8% with LAT and 17% with BIM. |
Note:
f
0.01% and 0.03%.
Abbreviations: BAK, benzalkonium chloride; BIM, bimatoprost (0.03%); CI, confidence interval; LAT, latanoprost (0.005%); PG, prostaglandin; TAF, tafluprost (0.0015%); TIM, timolol; TRA, travoprost (0.004%).